Grammati Sarri
Overview
Explore the profile of Grammati Sarri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarri G, Vinals L, Leisle L, Chau I, Smalbrugge D, Lucassen K, et al.
J Comp Eff Res
. 2025 Feb;
:e240240.
PMID: 40008768
Under the newly instituted health technology assessment (HTA) regulation (HTAR), health technology developers must build evidence packages that meet the needs for both the upcoming EU joint clinical assessment (JCA)...
2.
Abogunrin S, Muir J, Zerbini C, Sarri G
Front Pharmacol
. 2025 Feb;
16:1454245.
PMID: 39959426
Introduction: Researchers are increasingly exploring the use of artificial intelligence (AI) tools in evidence synthesis, a labor-intensive, time-consuming, and costly effort. This review explored and quantified the potential efficiency benefits...
3.
Muir J, Radhakrishnan A, Ozer Stillman I, Sarri G
Clinicoecon Outcomes Res
. 2024 Aug;
16:581-596.
PMID: 39184340
Cost-effectiveness analyses (CEA) are important in healthcare decision-making and resource allocation; however, expanding the scope of CEAs beyond the traditional clinicoeconomic concepts to also include value elements such as health...
4.
Sarri G, Hernandez L
J Comp Eff Res
. 2024 Aug;
13(9):e240061.
PMID: 39132748
Regulatory and health technology assessment (HTA) agencies have increasingly published frameworks, guidelines, and recommendations for the use of real-world evidence (RWE) in healthcare decision-making. Variations in the scope and content...
5.
Freitag A, Sarri G, Ta A, Gurskyte L, Cherepanov D, Hernandez L
Pharmacoeconomics
. 2024 Jun;
42(9):955-1002.
PMID: 38918342
Background And Objective: Multiple myeloma is a rare incurable hematological cancer in which most patients relapse or become refractory to treatment. This systematic literature review aimed to critically review the...
6.
Vinals L, Radhakrishnan A, Sarri G
Int J Equity Health
. 2024 May;
23(1):93.
PMID: 38720282
Background: Health disparities, starkly exposed and exacerbated by coronavirus disease 2019, pose a significant challenge to healthcare system access and health outcomes. Integrating health inequalities into health technology assessment calls...
7.
Adamson B, Makady A, Sarri G, Mohamed O, Babar Z, Dawoud D
Front Pharmacol
. 2024 May;
15:1396034.
PMID: 38698818
No abstract available.
8.
Sarri G, Rizzo M, Upadhyaya S, Paly V, Hernandez L
J Comp Eff Res
. 2024 Jan;
13(2):e230145.
PMID: 38226913
There is an urgent need for expedited approval and access for new health technologies targeting rare and very rare diseases, some of which are associated with high unmet treatment needs....
9.
Appiah K, Rizzo M, Sarri G, Hernandez L
J Comp Eff Res
. 2024 Jan;
13(2):e230140.
PMID: 38174576
The drive to expedite patient access for diseases with high unmet treatment needs has come with an increasing use of single-arm trials (SATs), especially in oncology. However, the lack of...
10.
Freitag A, Gurskyte L, Sarri G
J Comp Eff Res
. 2023 Aug;
12(10):e230046.
PMID: 37602779
Failure to adjust for effect modifiers (EMs) in indirect treatment comparisons (ITCs) can produce biased and uncertain effect estimates. This is particularly important for health technology assessments (HTAs), where the...